Few products have done more for humanity, and earned less from it, than antibiotics. Their success has become their undoing: the better they work, the less they sell. Drugmakers have moved on to more profitable ailments, and the antibiotic pipeline has quietly run dry. Meanwhile, as antimicrobial resistance (AMR) proliferates, our current antibiotics become less effective against resistant mutants. Without novel antibiotics, what was once modern medicine's most reliable safety net is now fraying, and the toll is starting to show.
According to global estimates, 4.71 million deaths in 2021 were associated with AMR, far surpassing HIV and malaria's death toll. At this pace, annual deaths are forecasted to reach 8.22 million by 2050, resulting in an additional \$1 trillion in healthcare costs. These are daunting numbers, but not fate. With the right incentives, the world can outsmart the microbes yet. A combined approach of improved treatments, enhanced vaccination programmes and, most importantly, antibiotic innovation, could reduce costs by \$97 billion.
It seems an odd predicament. Drugs that underpin all modern healthcare are no longer worth developing. Understanding why quickly leads from biology to balance sheets.
The antibacterial market's value sits at around $42 billion. A large number certainly, but, at 3% of the pharmaceutical market, it pales in comparison to oncology, inflammation and diabetes. Antibiotics, being the miraculous drugs they are, typically involve treatments lasting less than two weeks. Their revenues are no match to those generated by chronic-disease drugs, characterised by long-term, repeated use. This has large implications for costly research and development investment.
Antibiotics are expensive to develop, more so than other drugs. Drugmakers must overcome the scientific hurdles of creating medicines that target live pathogens while navigating costly clinical trials (pre and post approval). The leap from preclinical research stage to achieving regulatory approval can take between 10-15 years, with a success rate under 3.5%. Unsurprisingly, investors aren't keen to take the risk, leaving a notable funding gap often referred to as the "valley of death". When these costs are weighed against potential revenues, antibiotic development becomes an unattractive proposition.
Generally, sustainable annual revenue for drug developers hovers around \$300 million, yet most antibiotic companies make between \$15 and \$50 million in annual sales. In comparison, chronic diseases generate over \$800 million annually. This stark difference highlights the challenges facing the financial sustainability of the antibiotic industry.
The antibiotic market faces several problems that limit profitability. For one, antibacterial drugs were among the earliest to be developed and marketed, with the sulphonamides in the 1930s and penicillin in 1945, making it a highly genericised market by now. Secondly, there is often a significant time lag between approval and clinical guidelines. Finally, more recently in the past decade, stewardship programs, while vital to combating AMR, can also reduce sales. They implement policies that curb unnecessary or excessive antibiotic prescribing, which while being recommended by the WHO, has led to a 10% reduction in prescriptions and roughly 28% drop in consumption rates.
Nonetheless, global antibiotic sales volumes have increased due to rising demand and broader use. Paradoxically, this has coincided with a stagnating total market value, which does not bode well for rising AMR.
The antibiotic industry has been shrinking in plain sight. What was once a crowded race among pharmaceutical giants has thinned to a handful of small biotech firms and university labs. The numbers tell the story. Big pharma's share of antibiotic R&D has tumbled from roughly 75% in the 1980s to under 20% today. The pipeline has withered accordingly: 21 approvals in the 1990s, 6 in the 2000s, and barely a dozen since. Of the latest batch, a third have already been shelved, their makers bankrupt or sold off before profits materialised. Achaogen, for instance, brought Plazomicin to market in 2018, only to file for bankruptcy a year later. Melinta Therapeutics followed a similar path. What remains of the field now rests with small biotech ventures and academic projects, neither equipped to supply a future with effective drugs against resistant pathogens.
The effects are not confined to the laboratory. As investment and capacity have ebbed, even the manufacture of long-established antibiotics has become precarious.
Shortages have gradually developed from mostly temporary local incidents to persistent worldwide phenomena, especially in low and middle-income countries. Shortages are common in the pharmaceutical industry, but, worryingly, they are 42% more likely for antibiotics. Fragility in antibiotic supply reflects the same incentives that have thinned innovation. With low margins, high compliance costs, and heavy reliance on imported raw materials (notably active pharmaceutical ingredients from China and India), manufacturers have little reason to maintain excess capacity. A single factory outage can leave whole regions short of essential drugs.
When antibiotics run short, doctors must improvise: Doctors may delay treatments, or be forced to turn to broader-spectrum alternatives that, although reasonably effective, may act as breeding grounds for resistance. During the 2023 amoxicillin shortage, nearly half of hospital databases in the US, UK, and Belgium reported drops of a third or more in use, forcing widespread substitutions and rationing. Pharmacists spend hours juggling backorders, wards report cost overruns and patients stay longer in care.
Governments and health institutions have not been idle. Stewardship programs, regulations, and incentive schemes aim to curb resistance and stabilize supply. Yet, despite these measures, the imbalance persists.
Push incentives have been introduced, notably CARB-X, which provides partial public and private funding for early R&D. This support is critical for developers pursuing needed antibacterials. Unfortunately, none of these well-meant incentives shield a company from commercial failure. Achaogen's collapse, often blamed on overspending and a narrow market, also exposed a flaw that runs deep: the economics of antibiotics simply do not add up. Once a new drug is approved, stewardship limits its sales, leaving small biotechs without steady revenue to offset the hundreds of millions sunk into development. With investors wary and larger firms long gone, these companies survive on dwindling cash and short-term funding rounds. Reaching break-even for a single antibiotic can cost $250–400 million, yet the average antibiotic developer on NASDAQ is valued at barely a tenth of what's needed to raise that sum. The result is a market where innovation succeeds scientifically but fails economically.
Pull incentives, much like the UK's PASTEUR Act and similar "subscription" or "market entry" models, delink profit from sales volume, aligning with stewardship goals by discouraging overuse. However, compared to push incentives, they lag behind and have been underfunded, struggling to scale up.
Regulation and slow approvals remain considerable deterrents. Paratek Pharmaceuticals, for example, suspended antibiotic development for around four years due to uncertainty around FDA guidelines and trial endpoints, delaying market entry and causing substantial financial loss.
Reviving antibiotic innovation requires a coordinated approach linking regulation, funding, and industry engagement. Harmonised regulatory requirements, paired with clear, science-based guidance on trial endpoints, would reduce uncertainty and shorten development times. This acts as a small but critical nudge that makes investors reconsider what currently looks like a high-risk, low-return market. Predictable regulatory frameworks also amplify the impact of incentives. Early-stage grants from CARB-X or the AMR Action Fund foment discovery, but without large, reliable pull rewards (such as €500 million market entry prizes or EU-level subscription schemes) investment alone cannot sustain a pipeline.
Additionally, public-private partnerships illustrate how collaboration between governments, academia, NGOs, and industry can pool expertise, share risk, and tackle challenges that no single actor could resolve. At the same time, enticing large pharmaceutical firms back into the space is essential, as their scale, regulatory experience, and global reach amplify the impact of both incentives and partnerships. Integrating these levers could finally revive the market. It would begin to correct the systemic imbalances that hollowed it, creating an environment where innovation, stewardship, and accessibility reinforce one another rather than work at cross-purposes.
Amid the calculus of profit and loss, the stakes are clear. Antibiotics underpin surgeries, cancer therapies, and pandemic response. Without new effective drugs, medical progress will stall. The economic burden of antimicrobial resistance already reaches billions annually, and unchecked, it could escalate into trillions through lost productivity, longer hospital stays and strained intensive care capacity. In a world still recovering from COVID-19, the absence of innovation risks intensifying future outbreaks, as secondary bacterial infections become harder to treat.
Systemic reform is needed: coherent push and pull incentives, streamlined regulatory frameworks, and renewed engagement from large pharmaceutical firms through public-private partnerships could restore a sustainable pipeline. Without alignment between public health priorities and market incentives, the consequences will extend beyond mortality to disrupt health systems and economic stability alike.